

PATENT Customer No. 22,852 Attorney Docket No. 6832.1429-03000

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:		#8B
Jerome Bequart et al.	Group Art Unit: 1653	Zita
Application No.: 10/073,118	Examiner: Not yet assigned	7-25-06
Filed: February 12, 2002		, 50, 50
For: ALBUMIN DERIVATIVES WITH THERAPEUTIC FUNCTIONS		
Commissioner for Patents Washington, DC 20231		

## PRELIMINARY AMENDMENT

Prior to the examination of the above application, please amend this application as follows:

## IN THE SPECIFICATION:

Sir:

Please insert the attached Sequence Listing (pages 1-18) at the end of the application.

On page 13, please replace the paragraph beginning on line 19 with the following new paragraph:



FINNEGAN, HENDERSON,

FARABOW, GARRETT, & DUNNER, L.L.P. 1300 I STREET, N. W. WASHINGTON, DC 20005 202-408-4000

The expression plasmids can also take the form of shuttle vectors between a bacterial host such as Escherichia coli and yeasts; in this case an origin of replication and a selectable marker that function in the bacterial host would be required. It is also possible to position restriction sites which are unique on the expression vector such that